Tiapride is a drug that selectively blocks D₂ and D₃ dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation + some more technical info. Chemically a substituted benzamide, tiapride displays high D2 and D3 receptor affinity with relatively low activity at serotonin and muscarinic receptors, which contributes to a profile of antipsychotic and antidyskinetic efficacy with limited anticholinergic effects. Pharmacokinetic characteristics include rapid oral absorption with peak plasma concentrations typically within 1 to 2 hours, an elimination half life generally in the range of about 3 to 6 hours, low plasma protein binding, and predominant renal excretion of unchanged compound. Therapeutic use is often dose titrated by indication and patient factors; concurrent hepatic or renal impairment requires careful monitoring and dose adjustment. Analytical monitoring during development and production relies on validated HPLC and LC-MS methods to confirm potency, purity, and the absence of genotoxic impurities.
Parent: Metoclopramide/ Tiapride
Parent: Tiapride
![N-[2-(Diethylamino)ethyl]-2-hydroxy-5-(methylsulfonyl)benzamide (Desmethyltiapride)](https://veeprho.com/wp-content/uploads/2024/08/N-2-Diethylamino-ethyl-2-hydroxy-5-methylsulfonyl-benzamide-Desmethyltiapride.png "N-[2-(Diethylamino)ethyl]-2-hydroxy-5-(methylsulfonyl)benzamide (Desmethyltiapride)")
Parent: Tiapride
Parent: Tiapride/ Tiapride Hydrochloride
Known related substances for tiapride include N-dealkylated and desethyl metabolites, minor oxidative products such as N-oxide species, deamination products, ring-modified degradation products, and trace levels of synthetic precursors or residual solvents. Typical quality control specifications applied by manufacturers and regulatory guidance commonly set individual identified impurities at or below 0.10 to 0.20 percent w by weight, unspecified single impurities at or below 0.05 to 0.10 percent w by weight, and total impurities generally limited to 0.5 to 1.0 percent w by weight, depending on the impurity profile and maximum daily exposure. Heavy metals are typically controlled to pharmacopeial limits, for example not exceeding 10 to 20 ppm where applicable, and residual solvents are restricted according to ICH Q3C threshold classes. Release and stability testing use validated assays to ensure related compounds remain within established limits across shelf life.
Tiapride is a selective D2 and D3 receptor antagonist with low affinity for muscarinic and serotonergic receptors; it does not fit the classic pharmacological definition of second generation atypical antipsychotics that have higher serotonin 5-HT2A versus D2 blockade, so it is better categorized as a dopamine selective or substituted benzamide antipsychotic rather than a prototypical atypical agent.
Common adverse effects include somnolence, dizziness, gastrointestinal disturbances such as nausea, and extrapyramidal symptoms including parkinsonism and akathisia at higher doses; less commonly orthostatic hypotension, hyperprolactinemia with associated endocrine effects, and allergic skin reactions can occur. Risk increases with dose and with concurrent central nervous system depressants; renal or hepatic impairment can alter exposure and side effect risk.
Tiapride, marketed in some regions under the name Tiapridal, is sometimes used off label for agitation and behavioral symptoms including those with an anxiety component, particularly in elderly or neuropsychiatric patients, but it is not a first line anxiolytic. Evidence and clinical practice vary by indication and region, and treatment should be guided by specialist assessment.
Tiapride has been used to treat tics, including in Tourette syndrome, and may reduce tic severity via D2/D3 antagonism; it is considered an option in some treatment algorithms, especially when dopamine blockade is appropriate and when clinicians prefer its receptor selectivity and tolerability profile compared with alternatives.
